Weight-Loss Drugs May Lower Cancer Risk in People with Diabetes, a Study Suggests
Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in cancer prevention.
Now, a study of 170,000 patient records suggests there's a slightly lower risk of obesity-related cancers in US adults with diabetes who took these popular medications compared to those who took another class of diabetes drug not associated with weight loss.
This type of study can't prove cause and effect, but the findings hint at a connection worth exploring. More than a dozen cancers are associated with obesity.
'This is a call to scientists and clinical investigators to do more work in this area to really prove or disprove this,' said Dr. Ernest Hawk of MD Anderson Cancer Center in Houston, who was not involved in the study.
The findings were released Thursday by the American Society of Clinical Oncology and will be discussed at its annual meeting in Chicago. The study, funded by the National Institutes of Health, was led by Lucas Mavromatis, a medical student at New York University's Grossman School of Medicine.
'Chronic disease and chronic disease prevention are some of my passions,' said Mavromatis, a former research fellow with an NIH training program.
GLP-1 receptor agonists are injections used to treat diabetes, and some are also approved to treat obesity. They work by mimicking hormones in the gut and the brain to regulate appetite and feelings of fullness. They don't work for everyone and can produce side effects that include nausea and stomach pain.
In the study, researchers analyzed data from 43 US health systems to compare two groups: people with obesity and diabetes who took GLP-1 drugs and other people with the same conditions who took diabetes drugs like sitagliptin. The two groups were equal in size and matched for other characteristics.
After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk of death from any cause compared to those who took the other type of diabetes drug. There were 2,501 new cases of obesity-related cancer in the GLP-1 group compared to 2,671 cases in the other group.
The effect was evident in women, but not statistically significant in men. The study couldn't explain that difference, but Mavromatis noted that differences in blood drug concentration, weight loss, metabolism or hormones could be at play.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Arabiya
a day ago
- Al Arabiya
‘I am not taking drugs!' Elon Musk denies media report
Elon Musk on Saturday denied a report that he used ketamine and other drugs extensively last year on the 2024 campaign trail. The New York Times reported Friday that the billionaire adviser to President Donald Trump used so much ketamine, a powerful anesthetic, that he developed bladder problems. The newspaper said the world's richest person also took ecstasy and mushrooms and traveled with a pill box last year, adding that it was not known whether Musk also took drugs while heading the so-called Department of Government Efficiency (DOGE) after Trump took power in January. In a post Saturday on X, Musk said: 'To be clear, I am NOT taking drugs! The New York Times was lying their ass off.' He added: 'I tried 'prescription' ketamine a few years ago and said so on X, so this not even news. It helps for getting out of dark mental holes, but haven't taken it since then.' Musk first dodged a question about his drug use at a bizarre farewell appearance Friday with Trump in the Oval Office in which the Tesla and SpaceX boss sported a noticeable black eye as he formally ended his role as Trump's main cost-cutter at DOGE, which fired tens of thousands of civil servants. News of the injury drew substantial attention as it came right after the Times report on his alleged drug use. The daily recalled erratic behavior such as Musk giving an enthusiastic Nazi-style salute in January of this year at a rally celebrating Trump's inauguration. Musk said he got the injury while horsing around with his young son, named X, when he told the child to hit him in the face. 'And he did. Turns out even a five-year-old punching you in the face actually is...' he added, before tailing off. Later Friday, when a reporter asked Trump if he was aware of Musk's 'regular drug use,' Trump responded: 'I wasn't.' 'I think Elon is a fantastic guy,' he added. Musk has previously admitted to taking ketamine, saying he was prescribed it to treat a 'negative frame of mind' and suggesting his use of drugs benefited his work.
Al Arabiya
a day ago
- Al Arabiya
White House says Trump withdrawing Musk ally as nominee to head NASA
US President Donald Trump is planning to withdraw his nomination of tech billionaire Jared Isaacman, a close ally of Elon Musk, to lead space agency NASA, the White House said Saturday. 'It's essential that the next leader of NASA is in complete alignment with President Trump's America First agenda and a replacement will be announced directly by President Trump soon,' the White House said, confirming a report by The New York Times that Isaacman's nomination was being withdrawn.
Arab News
a day ago
- Arab News
Trump pulls Musk ally's NASA nomination, will announce replacement
WASHINGTON: The White House on Saturday withdrew its nominee for NASA administrator, Jared Isaacman, abruptly yanking a close ally of Elon Musk from consideration to lead the space agency. President Donald Trump said he would announce a new candidate soon. 'After a thorough review of prior associations, I am hereby withdrawing the nomination of Jared Isaacman to head NASA,' Trump wrote on his Truth Social site. 'I will soon announce a new Nominee who will be Mission aligned, and put America First in Space.' Isaacman, a billionaire private astronaut who had been Musk's pick to lead NASA, was due next week for a much-delayed confirmation vote before the US Senate. His removal from consideration caught many in the space industry by surprise. Trump and the White House did not explain what led to the decision. Isaacman, whose removal was earlier reported by Semafor, did not respond to a request for comment. Isaacman's removal comes just days after Musk's official departure from the White House, where the SpaceX CEO's role as a 'special government employee' leading the Department of Government Efficiency created turbulence for the administration and frustrated some of Trump's aides. Musk, according to a person familiar with his reaction, was disappointed by Isaacman's removal. 'It is rare to find someone so competent and good-hearted,' Musk wrote of Isaacman on X, responding to the news of the White House's decision. Musk did not immediately respond to a request for comment. Despite Trump's decision, Isaacman thanked the president for considering him for the job. 'The past six months have been enlightening and, honestly, a bit thrilling. I have gained a much deeper appreciation for the complexities of government and the weight our political leaders carry," he wrote on X. "It may not always be obvious through the discourse and turbulence, but there are many competent, dedicated people who love this country and care deeply about the mission. That was on full display during my hearing, where leaders on both sides of the aisle made clear they're willing to fight for the world's most accomplished space agency," he said. So not having @rookisaacman as boss of NASA is bad news for the agency. Maybe a good thing for Jared himself though, since being NASA head right now is a bit of a Kobayashi Maru scenario — Jonathan McDowell (@planet4589) May 31, 2025 It was unclear whom the administration might tap to replace Isaacman. One name being floated is retired US Air Force Lt. Gen. Steven Kwast, an early advocate for the creation of the US Space Force and Trump supporter, according to three people familiar with the discussions. Isaacman, the former CEO of payment processor company Shift4, had broad space industry support but drew concerns from lawmakers over his ties to Musk and SpaceX, where he spent hundreds of millions of dollars as an early private spaceflight customer. The former nominee had donated to Democrats in prior elections. In his confirmation hearing in April, he sought to balance NASA's existing moon-aligned space exploration strategy with pressure to shift the agency's focus on Mars, saying the US can plan for travel to both destinations. As a potential leader of NASA's some 18,000 employees, Isaacman faced a daunting task of implementing that decision to prioritize Mars, given that NASA has spent years and billions of dollars trying to return its astronauts to the moon. On Friday, the space agency released new details of the Trump administration's 2026 budget plan that proposed killing dozens of space science programs and laying off thousands of employees, a controversial overhaul that space advocates and lawmakers described as devastating for the agency. Montana Republican Tim Sheehy, a member of the Senate Commerce, Science and Transportation committee, wrote on X that Isaacman 'was a strong choice by President Trump to lead NASA' in response to reports of his departure. 'I was proud to introduce Jared at his hearing and strongly oppose efforts to derail his nomination,' Sheehy said. Some scientists saw the nominee change as further destabilizing to NASA as it faces dramatic budget cuts without a confirmed leader in place to navigate political turbulence between Congress, the White House and the space agency's workforce. 'So not having (Isaacman) as boss of NASA is bad news for the agency,' Harvard-Smithsonian astronomer Jonathan McDowell said on X. So not having @rookisaacman as boss of NASA is bad news for the agency. Maybe a good thing for Jared himself though, since being NASA head right now is a bit of a Kobayashi Maru scenario — Jonathan McDowell (@planet4589) May 31, 2025 'Maybe a good thing for Jared himself though, since being NASA head right now is a bit of a Kobayashi Maru scenario,' McDowell added, referring to an exercise in the science fiction franchise Star Trek where cadets are placed in a no-win scenario.
